7.00

36.72% 1.88

After Hours: 7.41 0.41 +5.86%

Edesa Biotech Inc (EDSA)

Overview News Price History Financials Discussions Forecast Stock Split

Edesa Biotech Inc stock is traded at $7.00, with a volume of 9.06M. It is up +36.72% in the last 24 hours and up +582.93% over the past month. Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Previous Close:

$5.12

Open:

$5.27

24h Volume:

9.06M

Relative Volume:

2.36

Market Cap:

$58.44M

Revenue:

Net Income/Loss:

$-7.82M

P/E Ratio:

-6.1055

EPS:

-1.1465

Net Cash Flow:

$-8.00M

1W Performance:

+1.45%

1M Performance:

+582.93%

6M Performance:

+192.89%

1Y Performance:

+186.89%

1-Day Range:

$5.26

$8.13

1-Week Range:

$4.85

$8.13

52-Week Range:

$0.72

$8.74

Edesa Biotech Inc Stock (EDSA) Company Profile

Name

Edesa Biotech Inc

Sector

Healthcare (1114)

Industry

Biotechnology (620)

Phone

(905) 475-1234

Address

100 SPY COURT, MARKHAM, ON

Employee

Twitter

@EdesaBiotech

Next Earnings Date

2024-08-12

Latest SEC Filings

EDSA's Discussions on Twitter

Compare EDSA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EDSA Edesa Biotech Inc	7.00	42.74M	0	-7.82M	-8.00M	-1.1465
VRTX Vertex Pharmaceuticals Inc	462.49	118.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	759.05	80.02B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	706.03	43.52B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.42	42.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	287.33	32.13B	5.36B	287.73M	924.18M	2.5229

Edesa Biotech Inc Stock (EDSA) Latest News

Mar 12, 2026

EDSA SEC FilingsEdesa Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 12, 2026

Mar 10, 2026

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7% - MarketBeat

Mar 10, 2026

Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy - Stock Titan

Mar 10, 2026

Mar 09, 2026

Best Biotech Stocks To Follow Today – March 7th - Defense World

Mar 09, 2026

Mar 08, 2026

Edesa Biotech’s Paridiprubart Trial Success Spurs Market Optimism - StocksToTrade

Mar 08, 2026

Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com

Mar 08, 2026

Mar 07, 2026

Will Edesa Biotech Inc. stock attract more institutional investorsPortfolio Performance Report & Weekly Return Optimization Plans - Naître et grandir

Mar 07, 2026

Best Biotech Stocks To Follow TodayMarch 7th - MarketBeat

Mar 07, 2026

Edesa Biotech Surges Following Promising Clinical Data in ARDS Treatment - StocksToTrade

Mar 07, 2026

Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com

Mar 07, 2026

Velan Capital Investment Management LP Increases Stake in Edesa Biotech Inc - GuruFocus

Mar 07, 2026

Edesa Biotech reports FQ1 net loss of $2.2 million - MSN

Mar 07, 2026

Mar 06, 2026

Price Action: Will Edesa Biotech Inc announce a stock splitJuly 2025 Earnings & High Yield Equity Trading Tips - baoquankhu1.vn

Mar 06, 2026

Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares - MarketBeat

Mar 06, 2026

Edesa Biotech (EDSA) CEO-linked entity adds 10,000 shares in open-market buy - Stock Titan

Mar 06, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 06, 2026

Aug Mood: Can Edesa Biotech Inc be the next market leaderWatch List & Free Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 06, 2026

Mar 05, 2026

FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst - Defense World

Mar 05, 2026

Mar 03, 2026

Edesa Biotech (NASDAQ: EDSA) CEO adds 3,000 shares in open-market purchases - Stock Titan

Mar 03, 2026

Nijhawan group boosts Edesa Biotech (EDSA) stake to 19.99% in 13D/A - Stock Titan

Mar 02, 2026

Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan

Mar 02, 2026

[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan

Mar 02, 2026

EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Research Tree

Mar 02, 2026

Mar 01, 2026

Edesa Biotech Advances with Promising Phase 3 Outcomes - StocksToTrade

Mar 01, 2026

Edesa Biotech’s Paridiprubart Phase 3 Success Drives Optimism - timothysykes.com

Mar 01, 2026

Feb 28, 2026

Edesa Biotech’s Strategic Advances Boost Stock Outlook - StocksToTrade

Feb 28, 2026

Edesa Biotech Surpasses Expectations with Promising Phase 3 Data - timothysykes.com

Feb 28, 2026

EDSA Technical Analysis & ETF Price Forecast - Intellectia AI

Feb 28, 2026

Feb 26, 2026

Why Is Edesa Biotech, Inc. (EDSA) Stock Up Today? - Meyka

Feb 26, 2026

Feb 25, 2026

Why Did EDSA Stock Rally More Than 70% Today? - Asianet Newsable

Feb 25, 2026

Feb 24, 2026

Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com

Feb 24, 2026

Edesa Biotech stock surges on positive Phase 3 trial data By Investing.com - Investing.com Canada

Feb 24, 2026

Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com

Feb 24, 2026

Edesa Biotech reports mortality reduction in phase 3 trial By Investing.com - Investing.com Australia

Feb 24, 2026

Edesa Biotech Reports Positive Phase 3 Paridiprubart Results - TipRanks

Feb 24, 2026

Edesa Biotech reports mortality reduction in phase 3 trial - Investing.com

Feb 24, 2026

Edesa Biotech reports additional results from phase 3 paridiprubart study - marketscreener.com

Feb 24, 2026

Edesa Biotech shows significant 28-day mortality reduction in 278-patient Phase 3 study - TradingView

Feb 24, 2026

Mortality-cutting Phase 3 data boost Edesa Biotech (NASDAQ: EDSA) - Stock Titan

Feb 24, 2026

Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study - TradingView

Feb 24, 2026

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - GlobeNewswire

Feb 24, 2026

Feb 23, 2026

Update Recap: Can Edesa Biotech Inc expand into new marketsMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn

Feb 23, 2026

Feb 18, 2026

EDSA Should I Buy - Intellectia AI

Feb 18, 2026

Feb 14, 2026

Will Edesa Biotech Inc. stock benefit from infrastructure spending2025 Earnings Surprises & Accurate Technical Buy Alerts - mfd.ru

Feb 14, 2026

Feb 13, 2026